Transaction DateRecipientSharesTypePriceValue
10th July 2020William G. Rice168,891Open or private sale$6.05$1,021,790.55
10th July 2020Gregory K. Chow126,668Open or private sale$6.05$766,341.40
10th July 2020Jotin Marango62,835Open or private sale$6.05$380,151.75
2nd July 2020Jotin Marango20,946Open or private sale$6.34$132,793.45
24th June 2020Warren Whitehead12,000Open or private sale$6.73$80,760.00
24th June 2020Warren Whitehead5,000Open or private sale$6.78$33,900.00
24th June 2020Warren Whitehead7,000Exercise of derivative$2.60$18,200.00
24th June 2020Warren Whitehead5,000Exercise of derivative$1.02$5,100.00
23rd June 2020Warren Whitehead500Exercise of derivative$1.60$800.00
23rd June 2020Warren Whitehead10,000Exercise of derivative$1.12$11,200.00
Aptose Biosciences
Aptose Biosciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Aptose Biosciences, Inc. is a clinical-stage oncology company. The company engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes.

Ticker: APTO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 882361
Employees: 33
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags